spacer
home > white papers > Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites - ArisGlobal
WHITE PAPERS
logo_ArisGlobal3.JPG

ArisGlobal

phone +1 203 588-3000
email clinicalteam@arisglobal.com
web http://www.totalclinical.com
email 1266 East Main Street, Stamford, CT 06902 US

Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites

ArisGlobal LLC

Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Turkish Cargo adds Kuala Lumpur and Ahmedabad to its cargo flight network.

The fastest growing global air cargo brand Turkish Cargo continues to expand its cargo flight network. The successful air cargo carrier has added Malaysian capital Kuala Lumpur (KUL) and the western Indian city of Ahmedabad (AMD) among the destinations to which it performs direct cargo flights.
More info >>


White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>


Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement